Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Social interaction and drug attitude effectiveness in patients with schizophrenia.

Tsai JK, Lin WK, Lung FW.

Psychiatr Q. 2011 Dec;82(4):343-51. doi: 10.1007/s11126-011-9177-z.

PMID:
21499787
2.

The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.

Kim SW, Yoon JS, Kim YS, Ahn YM, Kim CE, Go HJ, Chee IS, Jung SW, Chung YC, Kim YD, Joe S, Lee J, Kwon YJ, Yoon BH, Jae YM.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Aug 7;38(2):228-35. doi: 10.1016/j.pnpbp.2012.04.004. Epub 2012 Apr 10.

PMID:
22516251
3.
4.

Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia.

Patrick DL, Burns T, Morosini P, Rothman M, Gagnon DD, Wild D, Adriaenssen I.

Curr Med Res Opin. 2009 Feb;25(2):325-38. doi: 10.1185/03007990802611919 .

PMID:
19192977
5.

Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR).

Schreiner A, Hargarter L, Hitschfield K, Lee JI, Lenskaya I, Sulaiman AH, Diels J; PILAR study group.

Curr Med Res Opin. 2014 Jul;30(7):1279-89. doi: 10.1185/03007995.2014.898630. Epub 2014 Mar 19.

PMID:
24597755
6.

[Relationships between insight and medication adherence in subjects with psychosis].

Droulout T, Liraud F, Verdoux H.

Encephale. 2003 Sep-Oct;29(5):430-7. French.

PMID:
14615692
7.

Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.

Heres S, Don L, Herceg M, Bidzan L, Blanc M, Siracusano A, Maciulis V, Lahaye M, Schreiner A.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:207-12. doi: 10.1016/j.pnpbp.2013.09.015. Epub 2013 Oct 2.

PMID:
24096139
8.

Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS(®)) in the Swedish COAST-study.

Brain C, Allerby K, Sameby B, Quinlan P, Joas E, Karilampi U, Lindström E, Eberhard J, Burns T, Waern M.

Eur Neuropsychopharmacol. 2013 Dec;23(12):1754-62. doi: 10.1016/j.euroneuro.2013.09.001. Epub 2013 Sep 19.

PMID:
24091164
9.
10.

Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.

Canuso CM, Bossie CA, Amatniek J, Turkoz I, Pandina G, Cornblatt B.

Early Interv Psychiatry. 2010 Feb;4(1):64-78. doi: 10.1111/j.1751-7893.2010.00165.x.

PMID:
20199482
11.

Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.

Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M.

J Clin Psychiatry. 2008 May;69(5):817-29.

PMID:
18466043
12.

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.

Li H, Rui Q, Ning X, Xu H, Gu N.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1002-8. doi: 10.1016/j.pnpbp.2011.02.001. Epub 2011 Feb 18.

PMID:
21315787
13.

[Efficacy of paliperidone extended-release tablets in the improvement of social functions in schizophrenics: a randomized and controlled study].

Wang Y, Li WS, Gu DK, Yang N, Lu Y, Zhang Y, Cao Y, Bai LD.

Zhonghua Yi Xue Za Zhi. 2010 Aug 3;90(29):2030-5. Chinese.

PMID:
21029638
14.

[Drug compliance and health locus of control in schizophrenia].

Combes C, Feral F.

Encephale. 2011 May;37 Suppl 1:S11-8. doi: 10.1016/j.encep.2010.08.007. Epub 2010 Oct 8. French.

PMID:
21600328
15.

Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight.

Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC.

J Clin Psychiatry. 2004 Oct;65(10):1372-6.

PMID:
15491241
16.

DAI-10 is as good as DAI-30 in schizophrenia.

Nielsen RE, Lindström E, Nielsen J, Levander S.

Eur Neuropsychopharmacol. 2012 Oct;22(10):747-50. doi: 10.1016/j.euroneuro.2012.02.008. Epub 2012 Mar 21.

PMID:
22440974
17.

A pilot study of barriers to medication adherence in schizophrenia.

Hudson TJ, Owen RR, Thrush CR, Han X, Pyne JM, Thapa P, Sullivan G.

J Clin Psychiatry. 2004 Feb;65(2):211-6.

PMID:
15003075
18.

Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.

Canuso CM, Youssef EA, Bossie CA, Turkoz I, Schreiner A, Simpson GM.

Int Clin Psychopharmacol. 2008 Jul;23(4):209-15. doi: 10.1097/YIC.0b013e3282fce651.

PMID:
18545059
19.

Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.

Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, Healy D, Rae P, Power C.

Arch Gen Psychiatry. 2005 Jul;62(7):717-24.

PMID:
15997012
20.

Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.

Nasrallah H, Morosini P, Gagnon DD.

Psychiatry Res. 2008 Nov 30;161(2):213-24. doi: 10.1016/j.psychres.2007.11.012. Epub 2008 Oct 11.

PMID:
18848731

Supplemental Content

Support Center